Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Federal Trade Commission
Harvard Business School
Merck
Moodys
US Department of Justice
Daiichi Sankyo
Johnson and Johnson
Accenture
Mallinckrodt

Generated: October 20, 2017

DrugPatentWatch Database Preview

TWINJECT 0.15 Drug Profile

« Back to Dashboard

What is the patent landscape for Twinject 0.15, and when can generic versions of Twinject 0.15 launch?

Twinject 0.15 is a drug marketed by Impax Labs Inc and is included in one NDA. There are two patents protecting this drug.

This drug has forty-three patent family members in fifteen countries.

The generic ingredient in TWINJECT 0.15 is epinephrine. There are nineteen drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the epinephrine profile page.

Summary for Tradename: TWINJECT 0.15

US Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list9
Bulk Api Vendors: see list63
Patent Applications: see list8,173
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:TWINJECT 0.15 at DailyMed

Pharmacology for Tradename: TWINJECT 0.15

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Impax Labs Inc
TWINJECT 0.15
epinephrine
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS020800-002May 28, 2004DISCNNoNo► Subscribe► SubscribeY ► Subscribe
Impax Labs Inc
TWINJECT 0.15
epinephrine
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS020800-002May 28, 2004DISCNNoNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: TWINJECT 0.15

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,905,352Kits containing medicine injection devices and containers► Subscribe
7,931,618Apparatuses and methods for injecting medicines to a desired depth► Subscribe
8,187,224Methods performed by medicine injection apparatuses► Subscribe
7,927,303Medicine injection devices and methods► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: TWINJECT 0.15

Country Document Number Estimated Expiration
Taiwan200727928► Subscribe
China101072604► Subscribe
Canada2589899► Subscribe
China101072595► Subscribe
San MarinoP200700024► Subscribe
South Africa200704515► Subscribe
Australia2005314174► Subscribe
BrazilPI0518415► Subscribe
Canada2826821► Subscribe
Russian Federation2007125259► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
McKinsey
US Army
UBS
Accenture
Novartis
Fish and Richardson
Chubb
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot